Demonstration Of The Use Of Three Orthogonal Transposase Systems To Engineer CHO K1 Cells

By ATUM and Cergentis

While many consider the transposase enzyme to be the critical component necessary to developing high-expression cell lines, prioritizing transposon design is perhaps the most important variable to consider. This is true not only when seeking high expression levels of a therapeutic protein, but also in order to tightly control recombinant protein production and/or modulate endogenous gene expression up or down for various purposes. To facilitate broad access to transposase-mediated genome engineering, ATUM Bio has created its Leap-In Transposase® technology. The Leap-In platform builds on ATUM’s proven track record of optimizing protein expression by enabling robust and stable manufacturing cell line generation, resulting in a more efficient and lower-risk CMC development process.

To confirm that each transposon is integrated correctly and stably, Cergentis performs genetic characterization with their proprietary Targeted Locus Amplification (TLA) technology platform, coupled with next-generation sequencing (NGS). This allowed for the identification of the integration sites, as well as the integrity of the transposons. Furthermore, by comparing the TLA data of different time points, researchers were able to evaluate the genetic stability within the host cell genome. This technology provides improved insight into the genetic tailoring made possible by Leap-In, likewise representing an upgrade over traditional approaches to genomic analysis.